Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

er share.

Conference Call

Amylin will webcast its Quarterly Update Conference Call today at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. During the call, the Company plans to provide further details underlying its quarterly financial results, and information regarding assumptions for the remainder of 2009 operations.

The call will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com. A slide presentation accompanying the conference call will also be available through the "Investors" section of Amylin's corporate Web site. To access the webcast and slide presentation, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 730-5763 (U.S./Canada) or (857) 350-1587 (international), conference access code 44746855. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), conference access code 78094555.

Note Regarding Use of Non-GAAP Financial Measures

Amylin reports non-GAAP operating income (loss) excluding non-cash items and one-time items, which is a non-GAAP financial measure. The Company believes that investors' understanding of its progress towards its stated goal of generating sustainable positive non-GAAP operating results by the end of 2010 is enhanced by this disclosure. Amylin also reports non-GAAP research and development expenses net of cost-sharing payments, which is a non-GAAP financial measure. The Company believes that investors' understanding of Amylin's net investment in research and development activ
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... 29, 2014   ... will present data from a Phase I clinical trial ... or stop Parkinson,s disease progression. The Michael J. Fox ... and will discuss the impact of the results for ... Thursday, July 31, 2014       ...
(Date:7/29/2014)... 2014  Drug development for hepatitis C virus ... and the intense need for curative therapy in ... underway as the market moves away from protease ... interferon-free oral therapies. Logo - ... blockbuster Sovaldi is the first of these novel ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... May 2, 2012 Janssen Research & Development, LLC, ... Drug Applications (sNDAs) to the U.S. Food and Drug ... ® (rivaroxaban), an oral anticoagulant, to treat patients ... and prevention of recurrent venous thromboembolism (VTE). ...
... Official journal of the American Association for ... of scientific, technical and medical information products and services, announces ... American Association for Geriatric Psychiatry (AAGP) to publish ... AJGP ) beginning in January 2013. "We are ...
Cached Medicine Technology:Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 2Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 3
(Date:7/29/2014)... July 29, 2014 truBrain has created ... provided by energy drinks. Think Drinks , available ... that creates optimal conditions for memory, complex reasoning and ... hopes to raise $50,000 over the course of the ... mental boost and have compounding effects over time when ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Outsourced ... of tripling in the number of hospitals contracting ... 1, 2015 deadline, according to the recently published ... physician leaders, found in the reports “Top Ranked ... hospitals now outsource Clinical documentation audit, review and ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Biocides are ... and control bacteria or fungi growth and to prevent ... within the material and its surface. It is used ... wood preservation, food and beverage, paints and coatings. It ... and sanitizers, as well as in industrial applications to ...
(Date:7/29/2014)... increasing use of electronic medical records and health ... a computerized version of the preventive care guidelines ... new study, researchers from the Indiana University School ... substantial work lies ahead to convert the American ... prompts for physicians, but the payoff has the ...
(Date:7/29/2014)... 29, 2014 The Latin American poultry feed ... with analysis and forecast of revenue. The poultry feed and ... from $25,273.3 million and $647.2 million in 2013 to $34,024.0 ... 6.1% from 2013 to 2018, respectively. , To get an ... the TOC of the Latin American poultry feed and feed ...
Breaking Medicine News(10 mins):Health News:Focus- and Productivity-Enhancing Beverage Launches Crowdfunding Campaign on Indiegogo 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5
... be done without destroying embryo , , WEDNESDAY, July 9 ... in developing human embryonic stem cells earlier in the ... embryo, so the whole embryo is not destroyed. , ... European Society of Human Reproduction & Embryology annual conference ...
... Chest Pain Centers (SCPC) have been shown to perform ... Centers for Medicare and Medicaid Services (CMS) as compared ... by an Emory University researcher. , The ... director for observation medicine in the Emory University School ...
... Holdings, Inc.,(NYSE and SWX: ZMH) announced today its second ... live over the Internet on,Thursday, July 24, 2008, at ... results will be made available at 7:00 a.m. the,morning ... can be accessed via Zimmer,s Investor Relations,website at ...
... it comes to the attractiveness of orthodontic braces, less metal ... of the public,s attitude about the attractiveness of various styles ... no visible metal were considered the most attractive. Braces that ... were a less desirable option, and braces with metal brackets ...
... WEDNESDAY, July 9 (HealthDay News) -- Being born extremely underweight ... as an adult. , A study published in the July ... were born at extremely low birth weights were more likely ... had been born at normal weights. , And that ...
... - DaVita Medical Missions Reaches Out to Patients in Need of ... ... Bridge of Life - DaVita,Medical Missions(TM), a non-profit organization founded by DaVita ... to its newest dialysis clinic in India in late,June. The new clinic ...
Cached Medicine News:Health News:New Technique Harvests Stem Cells at Earlier Stage 2Health News:New Technique Harvests Stem Cells at Earlier Stage 3Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2Health News:Survey: Most effective dental braces are least attractive 2Health News:Survey: Most effective dental braces are least attractive 3Health News:Do Underweight Newborns Make for Shy Adults? 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 3
... Chalam 15° Prism are designed ... are recommended for tractional retinal ... Rhegmatogenus retinal detachment. They can ... and other midperipheral laser applications. ...
... The High-Mag 1.5x ... internal limiting membrane peeling ... optic nerve neurotomy, sheathotomy ... traditional macular edema and ...
... visualization of virtually the entire retina including ... of the lens on the eye. It ... giant retinal tears, diagnosing and treating anterior ... retina in a vitreous cavity filled with ...
... higher magnification and increased stereopsis, ... suited for detailed visualization to ... Retinal is ideal for vitrectomy ... peeling in proliferative vitreoretinopathy extending ...
Medicine Products: